These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 15291930

  • 21. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
    Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J.
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
    [Abstract] [Full Text] [Related]

  • 22. Glaucoma prescribing trends in England 2000 to 2012.
    Connor AJ, Fraser SG.
    Eye (Lond); 2014 Jul; 28(7):863-9. PubMed ID: 24858531
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy as initial treatment in glaucoma and suspected glaucoma.
    Mikelberg FS, Etminan M.
    Can J Ophthalmol; 2012 Jun; 47(3):240-2. PubMed ID: 22687299
    [Abstract] [Full Text] [Related]

  • 24. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
    van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH.
    Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
    [Abstract] [Full Text] [Related]

  • 25. Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017.
    Perera N, Pinnuck BC, Jamieson MPH, Ling D, Williams M, Chen O.
    J Glaucoma; 2020 Mar; 29(3):175-183. PubMed ID: 31790066
    [Abstract] [Full Text] [Related]

  • 26. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC, Konstas AG, Nelson LA, Kruft B.
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [Abstract] [Full Text] [Related]

  • 27. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study.
    Koleva D, Motterlini N, Schiavone M, Garattini L, Study Group GLAUCO.
    Ophthalmologica; 2007 Jul; 221(5):340-7. PubMed ID: 17728557
    [Abstract] [Full Text] [Related]

  • 28. [Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].
    Yu A, Welge-Lüßen U.
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):127-32. PubMed ID: 23335086
    [Abstract] [Full Text] [Related]

  • 29. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G.
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [Abstract] [Full Text] [Related]

  • 30. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR, Lunt DW, Fehrsen GS, Lombard CJ, Steyn K.
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [Abstract] [Full Text] [Related]

  • 31. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P, Bret MC, Queuille E.
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [Abstract] [Full Text] [Related]

  • 32. Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis.
    De Natale R, Le Pen C, Berdeaux G.
    J Glaucoma; 2011 Apr; 20(4):234-9. PubMed ID: 21682002
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P.
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [Abstract] [Full Text] [Related]

  • 34. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y.
    J Glaucoma; 2008 Feb; 17(3):233-7. PubMed ID: 18414111
    [Abstract] [Full Text] [Related]

  • 35. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
    Trese MGJ, Lewis AW, Blachley TS, Stein JD, Moroi SE.
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
    [Abstract] [Full Text] [Related]

  • 36. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S, Travatan Dosing Aid Study Group.
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [Abstract] [Full Text] [Related]

  • 37. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007.
    Lin JC.
    J Glaucoma; 2015 Nov; 24(5):364-71. PubMed ID: 26039384
    [Abstract] [Full Text] [Related]

  • 38. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M, Kravzov-Jinich J, Guadarrama-Atrizco MD, Rubio-Poo C, Wertheimer AI.
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [Abstract] [Full Text] [Related]

  • 39. Chart documentation by general physicians of the glaucoma medications taken by their patients.
    Jampel HD, Parekh P, Johnson E, Miller R.
    Am J Ophthalmol; 2005 Aug; 140(2):344-5. PubMed ID: 16086971
    [Abstract] [Full Text] [Related]

  • 40. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Quigley HA.
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.